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Abstract
Purpose The aim of this study was to evaluate the outcome
of patients with patellar tendinopathy treated with platelet-
rich plasma injections (PRP). Additionally, this study exam-
ined whether certain characteristics, such as activity level or
previous treatment affected the results.
Methods Patients (n036) were asked to fill in the Victorian
Institute of Sports Assessment – Patellar questionnaire
(VISA-P) and visual analogue scales (VAS), assessing pain
in activities of daily life (ADL), during work and sports,
before and after treatment with PRP. Of these patients, 14
had been treated before with cortisone, ethoxysclerol, and/or
surgical treatment (group 1), while the remaining patients
had not been treated before (group 2).
Results Overall, group 1 and group 2 improved significantly
on the VAS scales (p<.0.05). However, group 2 also improved
on VISA-P (p0 .0.003), while group 1 showed less healing
potential (p0 0.060). Although the difference between group 1
and group 2 at follow-up was not considered clinically mean-
ingful, over time both groups showed a clinically significant
improvement.
Conclusion After PRP treatment, patients with patellar ten-
dinopathy showed a statistically significant improvement. In
addition, these improvements can also be considered clinically
meaningful. However, patients who were not treated before
with ethoxysclerol, cortisone, and/or surgical treatment
showed the improvement.
Introduction
Like tendinopathy of the elbow, rotator cuff and Achilles
tendon, tendinopathy of the patellar tendon (jumpers’ knee)
is caused by degenerative tearing of collagen fibres rather
than an acute inflammatory condition [1]. The underlying
cause is considered to be a failed healing response due to
poor tendon vascularity [2]. Lian et al. showed that hypo-
vascularity plays a role in patellar tendinopathy, and also
programmed cell death [3]. It causes substantial morbidity
during sporting or working activities [4]. The pain and
inability to perform sporting activities at the desired level
warrants a search for adequate treatment. The range of treat-
ments for patients with jumpers’ knee includes rest, ice,
electrotherapy, massage, concentric and/or eccentric exercise,
taping, corticosteroid injection, and surgery [5]. Feretti et al.
found that conservative treatment did not produce sufficient
relief of symptoms in those with jumper’s knee during a two-
year follow-up. In addition, a substantial number of patients
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needed surgery, which did not always result in satisfactory
outcomes [6]. Several studies have shown that extracorpo-
real shockwave therapy (ESWT) and sclerotherapy are
promising [7, 8]. Recently, a higher level of evidence
was reached showing ESWT to be ineffective in treating
jumpers’ knee in in-season jumping athletes [9]. Since
histopathological and biochemical evidence have indicated
that the underlying pathology of tendinopathy is not an
inflammatory tendinitis but a degenerative tendinosis, con-
servative therapy should be shifted from anti-inflammatory
strategies (e.g., NSAID’s and steroids) to a more biologi-
cal approach in which the tissue degeneration is arrested
and even reversed. The use of platelet-rich plasma injec-
tions (PRP) has shown promising results in vitro [10] and
in vivo, in lateral epicondylitis [11]. In contrast, the use of
PRP in Achilles tendinopathy was judged not to be of
value [12]. Therefore, the aim of this study was to eval-
uate the outcome of patients with patellar tendinopathy
treated with PRP. Furthermore, this study examined whether
certain characteristics, such as activity level and previous
treatment affected the outcome.
Methods
Participants
This prospective cohort study measured pain and sporting
ability in patients with chronic patellar tendinopathy (N036)
before and after treatment with PRP. Of these patients, 14 had
been treated with cortisone, ethoxysclerol and/or surgical
treatment before PRP injection (group 1), while the other 22
patients had not received an injection or surgical treatment
before (group 2). All patients had visited a physiotherapist and
eccentric exercises had been performed exhaustively before
being treated with PRP. The diagnosis of patellar tendinopathy
was made on clinical grounds (pain on resisted extension of
the knee located at the inferior pole of the patella). An addi-
tional MRI was performed in 21 (58.3 %) cases, showing
oedema at the origin of the patellar tendon at the apex patellae
in all cases. The mean follow-up period (in months) after
being treated with PRP was 18.4 (SD04.9). The study was
performed between March 2008 and June 2009 at the
Medinova Hospital in Rotterdam (The Netherlands). The
study protocol was approved by the Medical Ethics
Committee.
Platelet-rich plasma preparation
In the group randomised to receive PRP the patient’s
own platelets were collected using the Recover System
(Biomet Biologics, Warsaw, Indiana). This device uses a
desktop-size centrifuge with disposable cylinders to isolate
the platelet- and leukocyte-rich fraction from a small vol-
ume of the patient’s anticoagulated blood drawn at the time
of the procedure. A 27-ml sample of whole blood was
collected from the uninvolved arm into a 30-ml syringe that
contained 3 ml of sodium citrate. The platelet-rich fraction
was prepared according to the instructions for the use for the
Recover System. Approximately 3 ml of PRP was obtained
for each patient. The PRP was then buffered to physiological
pH using 8.4 % sodium bicarbonate and Bupivacaine HCL
0.5 % with epinephrine (1:200000) was added. No activating
agent was used. The total time from blood aspiration to
injection in the patients was about 30 minutes. No specialised
equipment, other than the centrifuge to process the Recover
disposable, was required. All procedures were performed in
the same office setting by an independent person certified for
blood management.
Injection technique
Approximately 1 ml of PRP with Bupivacaine HCL 0.5 %
and epinephrine (1:200000) was injected directly into the
area of maximum tenderness. Then the remaining PRP with
Bupivacaine HCL 0.5 % with epinephrine (1:200000;
±4 ml) was injected by the investigator using a 22-g needle
into the patellar tendon origin on the patella with a pepper-
ing technique. This technique involved a single skin portal
and then five penetrations of the tendon.
Post-procedure protocol
Immediately after the injection, the patient was rested in a
supine position without moving the leg for 15 minutes.
Patients were sent home with instructions to rest the leg
for approximately 24 hours. If necessary, patients were
allowed to use aminocetaphen, but the use of nonsteroidal
anti-inflammatory medication was prohibited. After 24
hours, patients were given a standardised stretching protocol
to follow for two weeks under the supervision of a physio-
therapist. A formal eccentric muscle and tendon-
strengthening program was initiated after this stretching.
At four weeks after the procedure, patients were allowed
to proceed with normal sporting or recreational activities as
tolerated. The procedure for L-PRP preparation, injection
technique and post-procedure protocol were identical to the
procedure described for the lateral epicondylitis randomised
controlled trial published previously, except for the stand-
ardised stretching protocol [11].
Instruments
Patients were asked to fill in the Victorian Institute of Sports
Assessment – Patellar questionnaire (VISA-P) and visual
analogue scales (VAS) before and after treatment with PRP.
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The VISA-P consists of eight questions [13, 14]. This
instrument assesses (i) pain symptoms, (ii) function, and (iii)
ability to play sport. As such, the VISA-P provides an
impression of the severity of jumper’s knee. Six out of eight
questions are scored on a visual analogue scale ranging from
0 (worst health) to 10 (perfect health). The maximum VISA-
P score for an asymptomatic fully performing individual is
100 points and the theoretical minimum is 0 points. The
internal consistency and test–retest reliability of the Dutch
questionnaire was acceptable [14].
A VAS is an instrument to quantify the amount of pain
reported by the patient. Scores can range from 0 (no pain) to
10 (severest pain). Patients were asked to fill in the level of
pain during activities of daily life (ADL), work activities,
and sport activities.
Statistical analyses
Descriptive statistics (frequencies, percentages, means, and
standard deviations) were used to present the available soci-
odemographic and clinical data at baseline. The groups
(treated before or not treated before) were compared with
Student t-tests or the Mann–Whitney U test and chi-square
test. The paired-samples test was used to compare the
VISA-P scores at follow-up with results assessed at baseline
(when the total group was analysed). The Wilcoxon signed-
ranks test was used to compare the VAS scores and VISA-P
scores at follow-up with the results assessed at baseline
(when group 1 and group 2 were analysed separately). In
addition, effect sizes (i.e., an objective and standardised
measure of the magnitude of an observed effect) were cal-
culated. An effect size (ES) between 0.1 and 0.3 is small,
0.3–0.5 is moderate, and an ES greater than 0.5 is consid-
ered as large [15]. A 15-point difference on the VISA-P
score was considered to represent a clinically meaningful
difference [14]. The level of statistical significance was set
at P<0.05. All statistical analyses were performed using the
Statistical Package for the Social Sciences (SPSS Chicago,
IL, USA, version 17.0).
Results
Table 1 shows the baseline characteristics of the total pop-
ulation of patients treated with PRP. The majority of the
patients were male (63.9 %) and were not previously treated
with cortisone, ethoxysclerol, and/or surgical treatment (n0
22; 61.1 %). Group 1 received different treatment combina-
tions: one patient received cortisone, ethoxysclerol and sur-
gical treatment (2.8 %), four patients received cortisone and
ethoxysclerol (11.1 %), four patients received cortisone and
surgical treatment (11.1 %), four patients received only
cortisone (11.1 %), and one patient received ethoxysclerol
(2.8 %). Table 2 shows the baseline characteristics of group
1 and group 2 separately. At baseline, group 1 and group 2
did not differ regarding demographic (age, sex) and clinical
characteristics (duration of complaints in months, Tegner
score) or the outcomes on VAS scores and VISA-P score.
Pain and sport activities
Before treatment with PRP, only two patients (5.6 %) indi-
cated that when they had no pain during sports, they were
able to perform up to 40 minutes without any pain. After
treatment with PRP, eight patients (22.2 %) were able to
exercise without pain. These patients were able to play for at
least 90 minutes without any pain, except for one patient
who was able to play 40–60 minutes without pain. Before
treatment, 13 patients (36.1 %) had pain, but were able to
continue performing (score range: 60 minutes or more).
After treatment, these numbers increased to 24 patients
(66.7 %; score: 60 minutes or more). Initially, 11 patients
(30.5 %) had such pain that they were not able to finish the
training (score range: 30 minutes or more). However, after
PRP treatment only four patients (11.1 %) had to quit during
a training session (score range: 30 minutes or more).
Table 1 Baseline characteristics for the total population of patients
with patellar tendinopathy treated with gravitational platelet separation
Characteristics Values (N036)
Gender (men/women) 23 (63.9 %) / 13 (36.1 %)
Age (mean ± SD) 30.9±12.6
Cortisone (yes/no) 13 (36.1 %) / 23 (63.9 %)
Ethoxysclerol (yes/no) 6 (16.7 %) / 30 (83.3 %)
Surgical treatment (yes/no) 5 (13.9 %) / 31 (86.1 %)
Duration of complaints in mon
ths (mean ± SD)
40.3±28.4
VAS ADL score (mean ± SD) 4.0±2.7
VAS work score (mean ± SD) 3.6±3.9
VAS sport score (mean ± SD) 1.4±0.8
VISA-P total score (mean ± SD) 57.7±25.4
SD standard deviation, VAS visual analogue scale, ADL activities in
daily life, VISA-P Victorian Institute of Sports Assessment – Patellar
questionnaire
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Changes in pain after PRP injection
The total group significantly improved after being treated with
PRP. That is, mean scores on VISA-P improved from 40.1
(SD015.6) to 57.7 (SD025.4), with t(35)0−3.986,
p<0.0001, and ES0 0.56. VAS ADL decreased from 5.9 to
2.7 (p<0.0001, ES0−0.51), VAS work decreased from 6.3 to
3.2 (p<0.0001, ES0−0.50), and VAS sport decreased from
8.50 to 4.61 (p<0.0001, ES0−0.55).
The effect of pre-treatment on outcome
Mean scores on VISA-P significantly improved in group 2
from 39.1 (SD016.6) to 58.6 (SD025.4), with t(21)0−3.339,
p<0.003, and ES00.59. Group 1 did not show significant
improvement on VISA-P [t(13)0−2.060, p00.060].
However, VAS ADL scores, VAS sport scores, and VASwork
scores significantly improved in both groups (see Table 3).
Effect sizes ranged from −0.32 to −0.56. Both groups showed
a clinically meaningful improvement on VISA-P. The differ-
ence between group 1 and group 2 at follow-up was not
considered clinically meaningful.
Discussion
PRP treatment results in statistically significant improvement
in patients with chronic patellar tendinopathy compared with
the pre-injections status. Furthermore, these improvements
can be considered clinically meaningful. Those patients who
were not treated before with ethoxysclerol, corticosteroid,
and/or surgical treatment before entering this prospective
study, showed the largest improvement and thus showed the
largest healing potential.
The use of platelet-rich plasma as a treatment for chronic
patellar tendinopathy reflects its use in other tendons and
ligaments. There is increasing interest in sports medicine
and orthopaedics in endogenous growth factors to relieve
symptoms of degeneration of tendons and to counteract the
failed healing response, which is characteristic of these
injuries, to potentiate a faster return to sports and daily life
activities. Despite this interest, and apparent widespread
use, there is a lack of high-level evidence from randomised
clinical trials assessing the efficacy of PRP in treating liga-
ment and tendon injuries. Basic science and animal studies
and small case series reports on PRP injections for ligament
or tendon injuries, but few randomised controlled clinical
trials have assessed the efficacy of PRP injections and none
have demonstrated scientific evidence of efficacy. Scientific
studies should be performed to assess clinical indications,
efficacy, and safety of PRP, and this will require appropri-
ately powered randomised controlled trials with adequate
and validated clinical and functional outcome measures and
sound statistical analysis. Other aspects of PRP use that
need to be determined are (1) volume of injection/applica-
tion, (2) most effective preparation, (3) buffering/activation,
Table 2 Baseline characteristics for patients with patellar tendinopathy (group 1 and group 2)
Characteristics Group 1 (N014) Group 2 (N022) P-value
Gender (men/women) 9 (64.3) / 5 (35.7) 14 (63.3) / 8 (36.4) 0.886
Age (mean ± SD) 28.7±9.3 32.2±14.8 0.399
Cortisone (yes/no) 13 (92.2) / 1 (7.1) – –
Ethoxy (yes/no) 6 (42.9) / 8 (57.1) – –
Surgical treatment (yes/no) 5 (35.7) / 9 (63.4) – –
Duration of complaints in months (mean ± SD) 38.5±20.1 41.4±33.0 0.774
Tegner score (VISA-P item 7)
No, not at all 3 (21.4) 4 (18.2) 0.556*
Modified training or activity 6 (42.9) 8 (36.4)
Full training/competition but not at same level as
when symptoms began
5 (35.7) 6 (27.3)
Competing at the same level as symptoms began 0 (0.0) 4 (18.2)
SD standard deviation, VISA-P Victorian Institute of Sports Assessment – Patellar questionnaire
Percentages are given in parentheses. Group 1 is treated before with ethoxy, cortisone and/or surgical treatment, while group 2 is not
a The Tegner score was dichotomised (0 0 no not all/modified training or activity; 1 0 full training/competing at the same level as symptoms
began), since the expected cell count in the chi-square test based on the original scoring system was too low
Table 3 Means and standard deviations of VISA-P and VAS scores at
baseline and follow-up
Evaluation Baseline Follow-up P-value Effect size
Group 1 (n014)
VISA-P 41.8±14.3 56.3±26.2 0.093 −0.32
VAS ADL 6.5±2.3 2.8±2.2 0.005 −0.53
VAS work 6.9±2.5 3.1±2.5 0.005 −0.53
VAS sport 8.6±0.9 3.8±2.9 0.003 −0.56
Group 2 (n022)
VISA-P 39.1±16.6 58.6±25.4 0.003 −0.45
VAS ADL 5.6±2.9 2.6±2.7 0.001 −0.51
VAS work 6.0±3.0 3.2±2.9 0.001 −0.49
VAS sport 8.5±1.1 5.1±3.2 <0.0001 −0.55
VISA-P Victorian Institute of Sports Assessment – Patellar question-
naire, VAS visual analogue scales, ADL activities in daily life
Group 1 was treated before with ethoxy, cortisone and/or surgical
treatment, while group 2 was not
1944 International Orthopaedics (SICOT) (2012) 36:1941–1946
(4) injection technique (1 depot vs. multiple depots), (5)
timing of injection to injury, (6) single application versus
series of injections, and (7) the most effective rehabilitation
protocol to use after PRP injection [16].
This small series is not randomised, although the data
were prospectively collected, and therefore the positive ef-
fect of PRP series does not represent the highest level of
evidence. On the other hand, it is the largest series of
patients with a chronic patellar tendinopathy treated with
PRP. Other reports [17–20] in literature describing the use of
PRP in patellar tendinopathy describe a positive influence of
PRP on the course of chronic patellar tendinopathy, al-
though all studies used, for instance, a different brand or
different concentrations. However, none of these studies
recognises the effect the previous treatments may have
had, as in our series. Only in the study of Filardo et al. it
was mentioned that after failing of previous treatments, PRP
still succeeded to diminish symptoms of patellar tendinop-
athy [17]. We saw improvement of symptoms in our study in
those refractory cases when taking VAS for pain in daily life,
sports and work into account, but VISA-P scores did not show
improvement. Although an MRI was performed in 21 cases
before the injection of L-PRP, showing oedema at the origin of
the patellar tendon at the apex patellae, in only nine cases was
a post-injection MRI made, showing in fact a reduction of
oedema in seven cases. This small number of MRI scans does
not allow us to make a statement on the relation between
resolving symptoms and the MRI appearance.
There was a significant difference between those that had
chronic tendinopathy without previous failing therapies and
those with chronic tendinopathy of the same duration but
with previously failing treatments. In this study we mea-
sured large effect sizes in VAS for pain in daily life, sports
and work after the injection of PRP, thus a large change in
pain when PRP is injected, which is independent of whether
patients were treated before or treated for the first time. The
effect size for the VISA-P was in a different range, indicat-
ing less effect of the injection of PRP following previously
failed treatments such as injection of steroids, ethoxysclerol
or surgery. It is important to realize is that the duration of
complaints in months was not statistically different between
these two groups: the previously treated patients did not
have a longer history of symptoms. The well-known nega-
tive effects of repeated steroid injections were recently
emphasised by Coombs et al. [21] The effects of surgery
and ethoxysclerol were not described previously in relation
to the healing potential of a tendon, but this series shows
that previously treated patients have a smaller healing
potential.
It was also noted that the pain with sports decreased
significantly but most patients were still not pain free. This
is illustrated by the improvement in VAS, but not by the
improvement in VISA-P—the VISA-P scores the ability to
perform specific sporting activities without pain whereas the
VAS scores the level of pain during daily activities (ADL),
work activities, and sport activities. Although the athletes
were satisfied with this result it remains a point of interest.
In search for complete recovery a second procedure was
considered, but not attempted because of the experimental
nature of this treatment. Repeated injections might be ben-
eficial in patients who had suboptimal results after the initial
injection, although no evidence for a beneficial effect of
more than one injection exists. On theoretical grounds, by
studying the inflammation cascade in tendon repair, a rein-
jection after three to four weeks seems logical since at this
stage the cell proliferation and matrix deposition activity
will have peaked and can be expected to subsequently
decline. However, at this time no true indication of what
the result of a second injection would be can be determined.
Comparing our results with operative treatment in litera-
ture, we believe that these results may justify the implemen-
tation of a PRP injection before considering surgical
treatment of patellar tendinopathy. Surgical treatment has
been recommended when nonoperative treatment fails.
Open tenotomy and debridement proved to be a safe and
effective technique with 59 % excellent and 35 % good
results [22]. These percentages are higher than the results
presented here, especially with respect to sporting activities,
but since operative procedures in tendons in an athlete may
be detrimental for a career, PRP may be a safe and less
invasive way to create tendon healing.
Several other limitations should be acknowledged. The
needling/fenestration of tendinopathic tissue has a positive
effect itself on tendon healing. This study was not aiming to
show the difference between dry needling and the injection
of L-PRP, but showed a poorer healing potential in those
who had been previously treated, irrespective of the duration
of the symptoms that were classified as chronic in all cases.
In this study we used the multiple-penetration-of-the-ten-
don-technique. The reason for choosing this technique is, in
our opinion, not scientifically supported, but was made on
an empirical basis (we obtained good results in lateral epi-
condylitis) [11] and to closely follow the instructions pro-
vided by the manufacturer of the GPS III system (Biomet).
In this study, we used the clinically minimal difference of
the VISA-P to compare not only the treatment groups, but
also to determine whether such a difference is present over
time. However, no study has been performed to show
whether this clinically meaningful difference could be used
over time.
Another limitation of this study, apart from the fact that it
is a non-randomised and non-controlled study, is that al-
though this manuscript presents one of the largest samples
of patients with patellar tendinopathy treated with PRP, it is
too small to analyse the effect of the different treatment
combinations on the outcome. We were not able to show the
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logically existing relation between multiple previous treat-
ments and a less optimal outcome, although the results were
not as good as those patients who had previous failed injec-
tions with steroids or sclerosants. Both groups improved in
VAS for pain in daily life, sports and work, but VISA-P shows
no significant improvement in those who had been treated
before compared to those who only received PRP. Whether
this proves the lesser ability of PRP to jump-start the healing
mechanism, which was stopped by ethoxysclerol, steroid or
surgery, or just proves the worsening effect of those treatment
methods, remains to be seen. Yet, the results suggest that there
may be a relationship between prior treatments and efficacy of
PRP therapy for chronic patellar tendinopathy. This relation-
ship needs further studies powered to detect such a difference.
Open Access This article is distributed under the terms of the
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